EP Patent

EP4512392A2 — Orally-administered preparation containing solifenacin and tamsulosin

Assigned to Adalvo Ltd · Expires 2025-02-26 · 1y expired

What this patent protects

the present invention relates to a bilayer tablet for oral administration comprising (1) a first modified release layer comprising tamsulosin or a pharmaceutically acceptable salt thereof and a matrix forming polymer and (2) a second immediate release layer comprising solifenacin…

USPTO Abstract

the present invention relates to a bilayer tablet for oral administration comprising (1) a first modified release layer comprising tamsulosin or a pharmaceutically acceptable salt thereof and a matrix forming polymer and (2) a second immediate release layer comprising solifenacin or a pharmaceutically acceptable salt thereof and at least one water-insoluble diluent, wherein the tablet is optionally film coated.

Drugs covered by this patent

Patent Metadata

Patent number
EP4512392A2
Jurisdiction
EP
Classification
—
Expires
2025-02-26
Drug substance claim
No
Drug product claim
No
Assignee
Adalvo Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.